Thymic Health: A New Frontier in Predicting Immunotherapy Success for Cancer Patients

AI Study Unveils Thymic Health as Predictor of Immunotherapy Outcomes

A groundbreaking international study presented at the European Society for Medical Oncology (ESMO) Congress 2025 has revealed that the health of a cancer patient's thymus could be a crucial factor in predicting the success of immunotherapy treatments 1

1

2

2

. The research, led by Dr. Simon Bernatz from the AI in Medicine Program at Mass General Brigham, Boston, utilized artificial intelligence to analyze routine chest CT scans and assess thymic health in cancer patients.

The Thymus: A New Focus in Cancer Treatment

The thymus, a key component of the body's immune system responsible for T cell maturation, has long been overlooked in adult cancer patients. However, this study suggests that thymic health could be a missing piece in the puzzle of immunotherapy efficacy 1

1

. The researchers developed an AI-driven method to quantify thymic health from CT scans, assigning scores ranging from 0 to 100 based on various imaging features 1

1

.

Significant Findings Across Cancer Types

The study, which analyzed data from nearly 3,500 patients treated with immune checkpoint inhibitors, found that higher thymic health was associated with improved outcomes across various cancer types 2

2

3

3

. In non-small cell lung cancer patients:

• 35% lower risk of cancer progression (HR 0.65; 95% CI 0.54-0.77)
• 44% lower risk of death (HR 0.56; 95% CI 0.46-0.68)

Similar positive associations were observed in patients with melanoma, renal, and breast cancers 2

2

.

Validation and Biological Basis

To validate their findings, the researchers conducted a deeper analysis on a subgroup of 464 non-small cell lung cancer patients. They sequenced T-cell receptors and associated proteins, confirming that the AI-assessed thymic health correlated with T cell differentiation and function 2

2

3

3

.

Implications for Cancer Treatment

Dr. Bernatz suggests that thymic health could serve as a non-invasive biomarker of adaptive immune competence across various cancer types. This finding has the potential to enhance patient stratification in precision oncology and bring the patient's immune system into clinical decision-making alongside established tumor-centered biomarkers 1

1

2

2

.

Future Directions and Limitations

While the study's findings are promising, Dr. Alessandra Curioni-Fontecedro, Professor of Oncology at the University of Fribourg, Switzerland, notes that prospective validation is needed 2

2

3

3

. Future research may focus on using thymic health as a biomarker to guide treatment decisions, such as whether to administer immunotherapy alone or in combination with other treatments like chemotherapy.